Idera Pharmaceuticals, Inc. (IDRA)

Oncology Corporate Profile

Stock Performance

1.7700
-0.0200

HQ Location

167 Sidney Street
Cambridge, MA 2139

Company Description

Idera Pharmaceuticals is a clinical stage biotechnology company developing a novel approach to the treatment of autoimmune diseases and certain genetically defined forms of B-cell lymphoma. Our most advanced clinical programs are based on nucleic acid therapeutics designed to inhibit overactivation of Toll-like receptors. Idera is conducting clinical development of TLR antagonists in autoimmune and inflammatory diseases, and preclinical development of their use in certain genetically defined forms of B-cell lymphoma.

Website: http://www.iderapharma.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
IMO-2125 (+ ipilimumab)TLR9 agonistMelanomaI
IMO-2125TLR9 agonistVarious cancer typesPreclinical

Source: http://www.iderapharma.com/

Recent News Headlines

5/27/2017 06:18 am

5/27/2017 06:18 am

5/27/2017 06:18 am

5/27/2017 06:18 am

5/27/2017 06:18 am

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/10/2017 06:18 am

5/10/2017 06:18 am

5/10/2017 06:18 am

5/10/2017 06:18 am

5/10/2017 06:18 am

5/5/2017 12:18 pm

5/4/2017 12:18 pm

5/4/2017 06:18 am

5/4/2017 06:18 am

5/4/2017 06:18 am

5/4/2017 06:18 am

5/4/2017 06:18 am

4/21/2017 06:18 am

4/18/2017 12:18 pm

4/11/2017 12:17 am